Mitchell Shirvan
cso Silexion Therapeutics
Has served as the Chief Scientific and Development Officer of Silexion since April 2022. Prior to joining Silexion, Dr. Shirvan served as the Senior Vice President of R&D and V.P. Innovation and Discovery at Foamix Pharmaceuticals Ltd. from 2014 to 2019. Dr. Shirvan has over 25 years of industry experience, previously holding positions as Chief Executive Officer at Macrocure Ltd. from 2008 to 2012. From 1992 until 2008, Dr. Shirvan held various positions of increasing responsibility at Teva Pharmaceutical Industries, including Senior Director, Strategic Business Planning and Senior Manager, Research & Development. Prior to his tenure at Teva, he was a research fellow at the U.S. National Institutes of Health. Dr. Shirvan holds a Ph.D. in microbiology from The Hebrew University of Jerusalem and an MBA from the University of Bradford.
Seminars
- RNA interference (RNAi) gene-silencing technology offers high locus-level precision, reducing off-target effects with implications for a more favorable safety profile than small-molecule inhibitors
- siRNA directly targets oncogenic gene messengers, enabling intervention earlier in the cellular cancer cascade than other KRAS-directed strategies, with important implications for efficacy
- A unique dual-delivery approach maximizes drug exposure at the primary tumor, overcoming the stromal barrier, while simultaneously targeting micrometastases, two critical disease drivers for locally advanced pancreatic cancer with important efficacy and safety implications
